[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342063-105":59,"doc-detail-342063-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-combinatorial-immunotherapies-in-breast-cancer-a-systematic-review-and-meta-analysis","Impact of combinatorial immunotherapies in breast cancer - a systematic review and meta-analysis","","Breast cancer shows the highest female mortality burden worldwide, driving efforts to reduce deaths and improve patient quality of life. Resistance to conventional treatments remains a key obstacle, often linked to tumor microenvironment changes and treatment toxicity, affordability limits, and management complexity. This study synthesizes evidence on combinatorial immunotherapies, evaluating their effectiveness in breast cancer care by comparing combination regimens against mono-therapies on overall survival and progression-free survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-combinatorial-immunotherapies-in-breast-cancer-a-systematic-review-and-meta-analysis/342063/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-combinatorial-immunotherapies-in-breast-cancer-a-systematic-review-and-meta-analysis/342063.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study focusing on regarding breast cancer treatment?","Question",{"text":112,"@type":113},"The study analyzes the role and effectiveness of combinatorial immunotherapies in breast cancer management.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the evidence collected and analyzed?",{"text":117,"@type":113},"A systematic review and meta-analysis were conducted using randomized clinical trials (completed Phase I/II/III/IV) evaluating combination immunotherapies for breast cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes did combination immunotherapies show compared with mono-therapies?",{"text":121,"@type":113},"Combination immunotherapies significantly improved overall survival (OS) and progression-free survival (PFS) across multiple trial phases, with reported risk ratios and confidence intervals.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342063,1790334348,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Systematic Review PUBLISHED 16 October 2024  \nDOI 10.3389/fimmu.2024.1469441  \nOPEN ACCESS  \nEDITED BY  \nMohd Wajid Ali Khan,  \nUniversity of Hail, Saudi Arabia  \nREVIEWED BY  \nPriyanka S. Rana,  \nCase Western Reserve University, United States  \nLuciana Rodrigues Carvalho Barros, University of São Paulo, Brazil  \n*CORRESPONDENCE  \nShowket Hussain  \n showket. hussain@gov. in  \nRECEIVED 23 July 2024  \nACCEPTED 16 September 2024  \nPUBLISHED 16 October 2024  \nCITATION  \nSisodiya S, Kasherwal V, Rani J, Mishra N, Kumar S, Khan A, Aftab M, Shagufta, Singh P, Gupta E, Tanwar P and Hussain S (2024) Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis.  \nFront. Immunol. 15:1469441 .  \ndoi: 10.3389/fimmu.2024.1469441  \nCOPYRIGHT  \n© 2024 Sisodiya, Kasherwal, Rani, Mishra, Kumar, Khan, Aftab, Shagufta, Singh, Gupta, Tanwar and Hussain. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImpact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis  \nSandeep Sisodiya 1,2, Vishakha Kasherwal 1,2, Jyoti Rani 1,3, Neetu Mishra 2, Sandeep Kumar 1, Asiya Khan 4, Mehreen Aftab 1, Shagufta1,5, Payal Singh 1, Ekta Gupta 6, Pranay Tanwar4 and Showket Hussain 1*  \n1Cellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, India, 2Symbiosis School of Biological Sciences, Symbiosis International (Deemed University) (SIU), Pune, India, 3 Department of Zoology, Meerut College, C. C. S. University, Meerut, India, 4 Laboratory Oncology Unit, Dr. BRA-IRCH, All India Institute of Medical Sciences, New Delhi, India, 5 Depatment of Life Sciences, School of Basic Sciences and Research (SBSR), Sharda University, Greater Noida, India, 6 Division of Clinical Oncology, ICMR-National Institute of Cancer Prevention and Research, Noida, India  \nBackground: Breast cancer has the highest mortality rate among all cancers affecting females worldwide. Several new effective therapeutic strategies are being developed to minimize the number of breast cancer-related deaths and improve the quality of life of breast cancer patients. However, resistance to conventional therapies in breast cancer patients remains a challenge which could be due to several reasons, including changes in the tumor microenvironment. Attention is being diverted towards minimizing the resistance, toxicity, and improving the affordability of therapeutics for better breast cancer management. This includes personalized medicine, target-speciﬁc drug delivery systems, combinational therapies and artiﬁcial intelligence based screening and disease prediction. Nowadays, researchers and clinicians are also exploring the use of combinatorial immunotherapies in breast cancer patients, which have shown encouraging results in terms of improved survival outcomes. This study attempts to analyze the role of combinational immunotherapies in breast cancer patients, and offer insights into their effectiveness in breast cancer management.  \nMethodology: We conducted a systematic review and meta-analysis for which we selected the randomized clinical trials (RCTs) focused on completed Phase I/ II/III/IV clinical trials investigating combination immunotherapies for breast cancer. The analysis aimed to assess the efﬁcacy of combination therapies in comparison to mono-therapies, focusing on overall survival (OS), and progression-free survival (PFS) .  \nResults: We observed that, combination immunotherapies signiﬁcantly (P\u003C0 . 05) improved OS as compared to single-drug therapies in ","cbCainGWLNKlf0MA","https://ap.wps.com/l/cbCainGWLNKlf0MA","pdf",5933987,17,"English","# Background\n# Methodology\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the study focusing on regarding breast cancer treatment?\",\"answer\":\"The study analyzes the role and effectiveness of combinatorial immunotherapies in breast cancer management.\"},{\"question\":\"How was the evidence collected and analyzed?\",\"answer\":\"A systematic review and meta-analysis were conducted using randomized clinical trials (completed Phase I/II/III/IV) evaluating combination immunotherapies for breast cancer.\"},{\"question\":\"What outcomes did combination immunotherapies show compared with mono-therapies?\",\"answer\":\"Combination immunotherapies significantly improved overall survival (OS) and progression-free survival (PFS) across multiple trial phases, with reported risk ratios and confidence intervals.\"}]","Impact of combinatorial immunotherapies in breast cancer - a systematic review and meta-analysis | PDF",1790044967,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2aed1345234c8c7097e34d794230de62.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38b67d8311257e80031ea7ab04975667.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5f2773be1bf6608a7aad034d9712447.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de0e8af901215a03237138794efdaceb.webp",980,1385]